Synopsys (SNPS) Cash & Equivalents (2009 - 2025)

Synopsys has reported Cash & Equivalents for 17 years, with the latest figure at $2.9 billion in FY2025.

• For the quarter ending Q1 2026, Cash & Equivalents fell 98.82% year-over-year to $43.1 million; the trailing twelve-month figure through Jan 2026 stood at $43.1 million (down 98.82% YoY), and the FY2025 full-year result was $2.9 billion, down 25.92% from the prior year.
• Cash & Equivalents for FY2025 stood at $2.9 billion, down from $3.9 billion in the prior year.
• The five-year high for Cash & Equivalents was $3.9 billion in FY2024, with the low at $1.4 billion in FY2022.
• Historically, Cash & Equivalents has averaged $2.2 billion across 5 years, with a median of $1.6 billion in 2023.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 145.88% — and 2025, when it declined 25.92%.
• Synopsys' Cash & Equivalents stood at $1.4 billion in 2021, then retreated by 1.07% to $1.4 billion in 2022, then rose by 11.67% to $1.6 billion in 2023, then jumped by 145.88% to $3.9 billion in 2024, then decreased by 25.92% to $2.9 billion in 2025.
• The last three Cash & Equivalents figures came in at $2.9 billion (FY2025), $3.9 billion (FY2024), and $1.6 billion (FY2023), per Business Quant data.